PReS-FINAL-2319: PED-BD cohort 2013: expert consensus classification gives higher sensitivity than the international study group criteria to define Behcet's disease in children by I Koné-Paut et al.
POSTER PRESENTATION Open Access
PReS-FINAL-2319: PED-BD cohort 2013: expert
consensus classification gives higher sensitivity
than the international study group criteria to
define Behcet’s disease in children
I Koné-Paut1*, M Darce Bello1, F Shahram2, S Ozen3, R Cimaz4, H Michael5, M Gattorno6, B Chkirate7, K Bouayed8,
L Cantarini9, J Anton10, I Tugal-Tuktun11, J Kummerle-Deschner12, A Faye13, S Benamour14, TA Tran1, A Arnoux15,
PED-BD
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
BD is rarely encountered in children where the disease
is very difficult to recognize. The outcome ofpatients
with few symptoms is currently unknown
Objectives
To define the outcome of paediatric patients with at
least two symptoms of BD, and to obtain an appropriate
definition of BD in patients <16y.
Methods
An international expert committee has defined the criteria
of inclusion. New patients or patients followed for a maxi-
mum of 3 years, who presented at least 2 symptoms of BD
(among a list), and gave their informed consent were
included, reviewed yearly.
Results
228 patients were included since 2008, (SR: 1), from 22
centres of 13 countries, median age of 12.5y. Median age
at first symptom was 7.2y. Family history of BD was pre-
sent in 22% and consanguinity in 4.5%. Median disease
duration at inclusion was 4.7y and from the first symptom
to last visit was 7.5y. Inclusion criteria plus oral aphtosis
(mandatory) were (%): genital aphtosis 50, necrotic follicu-
litis 31, uveitis 28, familial history 22, pathergy positive 19,
erythema nodosum 15, vascular 10 and retinal vasculitis 7.
Mean number of symptoms: 1 plus family history 41%, 2
(33%), more than 3 (26%). Patient had a median of 1.3 fol-
low-up visit (0-4). 220 patients had a first visit, 138
patients had a 1-y visit (mean BD duration: 5.8y).
81 patients had 2-y (6.4y), 44 a 3-y (7.3y) and 18 a 4-y visit
(7.5y). The symptoms along the study were (%): dermato-
logical 67, genital aphtosis 52, articular 48, fever 47,
gastrointestinal 39, ocular 36, neurological 35, pathergy 17,
vascular 12, urological 2. HLAB51 was present in 47%.
Male patients had significantly more ocular and vascular
signs, female had more genital aphtosis. Between 1st-4th
visit: 57% had no new symptom, 24% had 1, 11% had 2
and 10% had more than 3. The expert committee has
examined 199 files at a median disease duration of 6,1y,
and classified 121 patients as definite, 18 as probable and
3 as not BD. 57 charts were reviewed but did not reached
consensus. 46 files have been reviewed more than once..
Among our patients classified as definite: 121/142 (85%);
79/121 (65%) fulfilled the ISG International criteria. Inter-
national criteria and expert classification showed signifi-
cant differences. Although good concordance (Kappa c =
0.72). Having 2 or more symptoms was significantly asso-
ciated with classification as definite BD (p = 0.0005).
Conclusion
The expert committee has classified the majority of
patients in the BD group although they did not fulfil the
international BD classification criteria (for adults).
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